about
Simultaneous enantiospecific separation and quantitation of mephenytoin and its metabolites nirvanol and 4'-hydroxymephenytoin in human plasma by liquid chromatography.An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics.A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens.Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients.A pharmacometric pulmonary model predicting the extent and rate of distribution from plasma to epithelial lining fluid and alveolar cells--using rifampicin as an example.Population pharmacokinetics of ethambutol in South African tuberculosis patients.A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients.Population pharmacokinetics, optimised design and sample size determination for rifampicin, isoniazid, ethambutol and pyrazinamide in the mouse.Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin.Population pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism--the Hokusai-VTE phase 3 studyA multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro.Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorptionEdoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism.Application of the Multistate Tuberculosis Pharmacometric Model in Patients With Rifampicin-Treated Pulmonary TuberculosisPopulation pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children.Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended dosesThe multistate tuberculosis pharmacometric model: a semi-mechanistic pharmacokinetic-pharmacodynamic model for studying drug effects in an acute tuberculosis mouse model.Improved power for TB Phase IIa trials using a model-based pharmacokinetic-pharmacodynamic approach compared with commonly used analysis methods.Analysis of opioid consumption in clinical trials: a simulation based analysis of power of four approaches.Intra- and extracellular activities of trimethoprim-sulfamethoxazole against susceptible and multidrug-resistant Mycobacterium tuberculosisPopulation Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial.Assessing Pharmacodynamic Interactions in Mice using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models.Repeated Time-to-event Analysis of Consecutive Analgesic Events in Postoperative Pain.The implications of model-informed drug discovery and development for tuberculosis.Evaluation of optimized bronchoalveolar lavage sampling designs for characterization of pulmonary drug distribution.Population pharmacokinetics of morphine and morphine-6-glucuronide following rectal administration--a dose escalation study.Model based design and analysis of phase II HIV-1 trials.A two-compartment effect site model describes the bispectral index after different rates of propofol infusion.Performance of nonlinear mixed effects models in the presence of informative dropout.Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9.The use of liquid chromatography/mass spectrometry for quantitative analysis of oxycodone, oxymorphone and noroxycodone in Ringer solution, rat plasma and rat brain tissue.Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine.Enantiospecific separation and quantitation of mephenytoin and its metabolites nirvanol and 4'-hydroxymephenytoin in human plasma and urine by liquid chromatography/tandem mass spectrometry.A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions.In vivo and mechanistic evidence of nuclear receptor CAR induction by artemisinin.In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics.A model-informed preclinical approach for prediction of clinical pharmacodynamic interactions of anti-TB drug combinations.
P50
Q30946826-7BE8F767-ADEE-465D-8FC1-94DE67D8DBB1Q31131623-06C3E1C3-195E-415F-A173-E051D6F52F2BQ33324419-403DCDE5-B25C-4B1A-B522-9FFFD9367D68Q33364134-44E920D4-1DD2-4D5E-A81F-5E71618925BFQ33605816-226B5EC0-0B37-4672-939C-01385495CE1AQ34123784-5FF0F399-7BDA-475E-9F4D-DCA7D9C1B831Q35097554-0DE7C74B-20AA-4252-9C83-3A25D024BC4FQ35191463-364F5348-18E5-4C9E-9D5E-96AE6DE85FDFQ35867335-381F9704-059C-4E8F-A53C-D4A8C73185C8Q36090144-45C42628-1EC1-46B3-B328-42787321B05BQ36111218-44B6EC0B-F01F-47A7-8E75-C66FD6488A1AQ36410089-EF7EC887-E6FD-449E-95E5-645CAF9DB7C7Q36684146-352BA96E-FBC5-4C3B-9178-36064F636F27Q36702972-0F9364FE-072A-4476-BFFC-1B6559C65386Q36840816-D91B97C0-BC9A-4CBD-9724-6497943DF9EAQ36918510-B1F7D557-389B-427C-B3A9-4AF68867F330Q37094229-3ED05AB6-2C9A-4D9C-AE1A-E4F863675D43Q37124090-307EEDBA-6F67-4C3E-8EFD-886EC2A79CF6Q37688266-5E555139-AC3E-4CBA-A04B-A8FD8A623E93Q37733488-D9E4749F-4D71-4C83-A375-07F1A923DE29Q38777021-73D43816-757E-4D52-A297-9BD3394E11F6Q38847054-9BDAF44F-9B71-40D4-A5E0-84D6E7B4C0C7Q38954085-40BEC09C-CE16-4165-82D7-777AC10DA03AQ39941768-361F77E6-6773-44AF-B590-229381760377Q40155324-B7AFEF43-A153-4118-8A43-FE5DBCD11A23Q40398946-B06C35B7-B1FD-4EF8-ABEA-6A4B1A8D8945Q40487917-68CC9CAC-519F-430C-A636-3DCC9EF2F759Q40598093-83CBDB28-3BB0-4708-B168-C46673B01FBDQ41716246-12E30B7F-2BCA-42EA-A2B8-B33143B6E770Q42284705-9B3291B5-F850-4730-9EBF-9B1B2537C4CDQ43087841-04BEE89D-885E-4FCE-ABF0-4F460487A7A2Q43096322-A8FEBF35-DB32-4CE5-8A16-57381D87F711Q44502138-86DB0E16-5840-4BDA-89C7-CD9B57BCBD77Q45093066-F286C8DD-A830-40B3-B4C0-5E785085DEB9Q46739660-5EC02E74-5C38-41D5-B016-FC2C6864D330Q46881594-1036155E-3F0D-4411-ADFE-DDF7537C5A9DQ47129748-A133AD81-7E70-4B44-88FE-F71DCC80E198Q48034439-DBD7F1BC-B2EE-4DBF-8F45-202F49EE7ACFQ48504949-81A66D32-A029-438A-A559-7122C33AB1EBQ50026490-B6365462-44E7-4D98-BBFB-86ACE6D613BF
P50
description
researcher
@en
wetenschapper
@nl
name
Ulrika S H Simonsson
@en
Ulrika S H Simonsson
@nl
type
label
Ulrika S H Simonsson
@en
Ulrika S H Simonsson
@nl
prefLabel
Ulrika S H Simonsson
@en
Ulrika S H Simonsson
@nl
P106
P31
P496
0000-0002-3424-9686